Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain

Navarro-Illana, Esther; López-Lacort, Mónica; Navarro-Illana, Pedro; Vilata, J.J.; Díez-Domingo, Javier

doi:10.1016/j.vaccine.2017.04.080

Cited by 54 publications

(52 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies have shown that the 2‐dose schedule has important benefits in comparison with the 3‐dose schedule, including potentially higher uptake, fewer side effects, cost‐effectiveness, and easier logistics . However, there may be reduced effectiveness with a reduced dosing schedule . Since October 2016, a 2‐dose schedule has been recommended for those who initiate the vaccine before the age of 15 years.…”

Section: Discussionmentioning

confidence: 99%

“…30,41 However, there may be reduced effectiveness with a reduced dosing schedule. 21,24,42 Since October 2016, a 2-dose schedule has been recommended for those who initiate the vaccine Hazard ratios were adjusted for the region and the history of sexually transmitted diseases and pregnancy.…”

Section: Discussionmentioning

confidence: 99%

“…However, efficacy progressively decreased among older age groups (18‐20 and 21‐25 years) . There are mixed results regarding evidence supporting a specific number of HPV vaccine doses being protective . Although the original effectiveness studies were conducted with the 3‐dose schedule, a 2‐dose schedule with doses spaced at least 6 months apart has shown important benefits in those who initiate their first dose before the age of 15 years, including easier logistics, reduced expenditures, potentially higher acceptance, and fewer side effects .…”

Section: Introductionmentioning

confidence: 99%

“…18 There are mixed results regarding evidence supporting a specific number of HPV vaccine doses being protective. 13,[20][21][22][23][24][25][26][27][28][29][30] Although the original effectiveness studies were conducted with the 3-dose schedule, a 2-dose schedule with doses spaced at least 6 months apart has shown important benefits in those who initiate their first dose before the age of 15 years, including easier logistics, reduced expenditures, potentially higher acceptance, and fewer side effects. 30 Although some population-based studies report that 1 vaccine dose protects against anogenital warts, 20-22 other studies show increased vaccine effectiveness with more doses.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Comparison of the long‐term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: A database study

Rodrı́guez

Zeybek

Vaughn

et al. 2020

Cancer

View full text Add to dashboard Cite

Background Human papillomavirus (HPV)–related disease remains a significant source of morbidity and mortality, and this underscores the need to increase HPV vaccination to reduce the burden of the disease. The objective of this study was to examine the association between the number of HPV vaccine doses and the risk of histologically confirmed preinvasive cervical disease and high‐grade cytology. Methods This retrospective matched cohort study used administrative data from Optum's Clinformatics DataMart Database to identify females aged 9 to 26 years who received 1 or more quadrivalent HPV vaccine doses between January 2006 and June 2015. Cases and controls were matched on region, age, sexually transmitted disease history, and pregnancy. All had a Papanicolaou test ≥1 year after the date of the matched case's final dose. Cox proportional hazards models were used to examine the association between the number of HPV vaccine doses and the incidence of preinvasive cervical disease and high‐grade cytology. The Kaplan‐Meier method was used to estimate the cumulative incidence rate at the 5‐year follow‐up. Results The study included 133,082 females (66,541 vaccinated and 66,541 unvaccinated) stratified by the number of HPV vaccine doses and the vaccine initiation age. Among those aged 15 to 19 years, the hazard ratio (HR) for high‐grade cytology for the 3‐dose group was 0.84 (95% confidence interval [CI], 0.73‐0.97), whereas the HRs for histologically confirmed preinvasive cervical disease for 1, 2, and 3 doses were 0.64 (95% CI, 0.47‐0.88), 0.72 (95% CI, 0.54‐0.95), and 0.66 (95% CI, 0.55‐0.80), respectively. Conclusions The receipt of 1, 2, or 3 doses of an HPV vaccine by females aged 15 to 19 years was associated with a lower incidence of preinvasive cervical disease in comparison with unvaccinated females, and this supports the use of any HPV vaccination in reducing the burden of the disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Comparison of the long‐term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: A database study

Rodrı́guez

Zeybek

Vaughn

et al. 2020

Cancer

View full text Add to dashboard Cite

show abstract

“…In countries with quadrivalent HPV vaccination programs, the rates of AGW have declined significantly in young women, and to a lesser extent in MSW, but not in MSM and older women , indicating that the demography of AGW patients will most likely change in the future. Better knowledge of STI among these subgroups is needed to stratify screening recommendations for MSW, MSM and women with AGW, respectively.…”

Section: Discussionmentioning

confidence: 99%

Sexually transmitted coinfections in patients with anogenital warts – a retrospective analysis of 196 patients

Mueller

Menzi

Kind

et al. 2020

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Background and objectives: Anogenital warts (AGWs) are most commonly caused by low-risk human papillomavirus (HPV) types, and although they are the most frequent viral sexually transmitted infections (STIs), little is known about STI coinfections in affected patients. We therefore sought to assess STI coinfection rates in patients with AGW, specify STI coinfections and calculate the number needed to screen (NNS) for each STI. Methods:A retrospective cross-sectional study analyzing data sets from AGW patients treated in our clinic between 2008-2016.Results: 142/196 (72 %) patients had been variably screened for infections with HIV, HBV and HCV, Treponema pallidum, Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium and HSV. The STI coinfection rate in all tested patients was 24.6 %, yielding an NNS of 4.1 to detect any STI. Of note, the coinfection rate did not differ significantly between heterosexual men, homosexual men and women, respectively. The NNS for syphilis was 8.4, for HIV 14.0, for HCV 28.5 and for HBV 39.0. The NNS for asymptomatic patients tested for HSV, Chlamydia trachomatis and Mycoplasma genitalium were 1.4, 5.3 and 12.0, respectively.Conclusion: Due to the high prevalence of STI coinfections, AGW patients should be screened for other STIs.

show abstract

RETRACTED ARTICLE: The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 6 Years After Approval

et al. 2019

View full text Add to dashboard Cite

Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain

Cited by 54 publications

References 31 publications

Comparison of the long‐term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: A database study

Comparison of the long‐term impact and clinical outcomes of fewer doses and standard doses of human papillomavirus vaccine in the United States: A database study

Sexually transmitted coinfections in patients with anogenital warts – a retrospective analysis of 196 patients

RETRACTED ARTICLE: The Longitudinal Incidence of Human Papillomavirus Vaccination in Spanish Primary Care in the First 6 Years After Approval

Contact Info

Product

Resources

About